Pierre Blier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11044346/publications.pdf

Version: 2024-02-01

14644 15249 126 17,902 216 66 citations h-index g-index papers 218 218 218 11547 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Current advances and trends in the treatment of depression. Trends in Pharmacological Sciences, 1994, 15, 220-226.	4.0	1,040
2	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 540-560.	0.9	746
3	Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends in Neurosciences, 1996, 19, 378-383.	4.2	626
4	Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry, 2014, 14, S1.	1.1	569
5	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2015, 29, 459-525.	2.0	528
6	Is there a role for 5-HT1A agonists in the treatment of depression?. Biological Psychiatry, 2003, 53, 193-203.	0.7	492
7	Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. JAMA Psychiatry, 2019, 76, 893.	6.0	472
8	Monoamine neurocircuitry in depression and strategies for new treatments. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 54-63.	2.5	432
9	Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: Electrophysiological studies in the rat brain. Synapse, 1987, 1, 470-480.	0.6	420
10	Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). International Journal of Neuropsychopharmacology, 2019, 22, 616-630.	1.0	404
11	Modifications of the Serotonin System by Antidepressant Treatments. Journal of Clinical Psychopharmacology, 1987, 7, 36S.	0.7	328
12	Long-Term Antidepressant Treatments Result in a Tonic Activation of Forebrain 5-HT1AReceptors. Journal of Neuroscience, 1998, 18, 10150-10156.	1.7	307
13	Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: Electrophysiological studies in the rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 1986, 333, 342-348.	1.4	290
14	Effectiveness of Pindolol With Selected Antidepressant Drugs in the Treatment of Major Depression. Journal of Clinical Psychopharmacology, 1995, 15, 217-222.	0.7	282
15	Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study. American Journal of Psychiatry, 2010, 167, 281-288.	4.0	276
16	Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. American Journal of Psychiatry, 2019, 176, 401-409.	4.0	266
17	Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. International Journal of Neuropsychopharmacology, 2008, 11, 625-639.	1.0	242
18	Serotonin and Drug-Induced Therapeutic Responses in Major Depression, Obsessive–Compulsive and Panic Disorders. Neuropsychopharmacology, 1999, 21, 91S-98S.	2.8	236

#	Article	IF	Citations
19	The pharmacology of putative early-onset antidepressant strategies. European Neuropsychopharmacology, 2003, 13, 57-66.	0.3	219
20	Brain Regional \hat{l}_{\pm} -[11C]Methyl-l-Tryptophan Trapping in Impulsive Subjects With Borderline Personality Disorder. American Journal of Psychiatry, 2001, 158, 775-782.	4.0	217
21	Serotonin and beyond: therapeutics for major depression. Philosophical Transactions of the Royal Society B: Biological Sciences, 2013, 368, 20120536.	1.8	188
22	Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive–compulsive disorder responses. Biological Psychiatry, 1998, 44, 313-323.	0.7	176
23	Alpha power, alpha asymmetry and anterior cingulate cortex activity in depressed males and females. Journal of Psychiatric Research, 2012, 46, 1483-1491.	1.5	173
24	Selective Activation of Postsynaptic 5-HT1A Receptors Induces Rapid Antidepressant Response. Neuropsychopharmacology, 1997, 16, 333-338.	2.8	155
25	Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 1988, 337, 246-254.	1.4	153
26	The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: The clinical guidelines International Journal of Neuropsychopharmacology, 2017, 20, pyw109.	1.0	151
27	Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology, 2001, 155, 52-57.	1.5	148
28	A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biological Psychiatry, 2004, 55, 553-555.	0.7	145
29	Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology, 2007, 22, 323-329.	0.9	137
30	Electrophysiological and neurochemical effects of long-term vagus nerve stimulation on the rat monoaminergic systems. International Journal of Neuropsychopharmacology, 2013, 16, 459-470.	1.0	136
31	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. European Neuropsychopharmacology, 2015, 25, 2318-2325.	0.3	135
32	Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxtryptamine system. British Journal of Pharmacology, 1997, 120, 865-875.	2.7	130
33	Cross-Talk between Dopaminergic and Noradrenergic Systems in the Rat Ventral Tegmental Area, Locus Ceruleus, and Dorsal Hippocampus. Molecular Pharmacology, 2008, 74, 1463-1475.	1.0	129
34	Clinical Evidence and Potential Neurobiological Underpinnings of Unresolved Symptoms of Depression. Journal of Clinical Psychiatry, 2008, 69, 246-258.	1.1	128
35	Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. International Journal of Neuropsychopharmacology, 2000, 3, 1-11.	1.0	125
36	Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. European Neuropsychopharmacology, 2009, 19, 457-465.	0.3	122

#	Article	IF	CITATIONS
37	Differential responsiveness of the rat dorsal and median raphe 5-HT systems to 5-HT1 receptor agonists and p-chloroamphetamine. Synapse, 1990, 5, 120-133.	0.6	121
38	Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Research, 2001, 922, 9-20.	1.1	121
39	Relevance of Norepinephrine–Dopamine Interactions in the Treatment of Major Depressive Disorder. CNS Neuroscience and Therapeutics, 2010, 16, e1-17.	1.9	119
40	Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant Strategy. Neuropsychopharmacology, 2011, 36, 1275-1288.	2.8	117
41	Enhancement of the function of rat serotonin and norepinephrine neurons by sustained vagus nerve stimulation. Journal of Psychiatry and Neuroscience, 2009, 34, 272-80.	1.4	117
42	Measurement of Brain Regional \hat{l} ±-[11C]Methyl-L-Tryptophan Trapping as a Measure of Serotonin Synthesis in Medication-FreePatients With Major Depression. Archives of General Psychiatry, 2004, 61, 556.	13.8	116
43	Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 362-373.	2.5	116
44	Differential physiological effects of a low dose and high doses of venlafaxine in major depression. International Journal of Neuropsychopharmacology, 2007, 10, 51.	1.0	115
45	Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 1-48.	1.8	113
46	Alteration of Serotonin Release in the Guinea Pig Orbito-Frontal Cortex by Selective Serotonin Reuptake Inhibitors Relevance to Treatment of Obsessive-Compulsive Disorder. Neuropsychopharmacology, 1995, 13, 117-127.	2.8	112
47	A Prospective, Longitudinal Study of the Effect of Remission on Cortical Thickness and Hippocampal Volume in Patients with Treatment-Resistant Depression. International Journal of Neuropsychopharmacology, 2015, 18, pyv037-pyv037.	1.0	107
48	Modulation of 5â€HT release in the guineaâ€pig brain following longâ€term administration of antidepressant drugs. British Journal of Pharmacology, 1994, 113, 485-495.	2.7	105
49	Short-term lithium administration enhances serotonergic neurotransmission: Electrophysiological evidence in the rat CNS. European Journal of Pharmacology, 1985, 113, 69-77.	1.7	99
50	Effects of the two antidepressant drugs mianserin and indalpine on the serotonergic system: Single-cell studies in the rat. Psychopharmacology, 1984, 84, 242-249.	1.5	97
51	In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of $\hat{l}\pm 2$ -adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 347, 266-272.	1.4	97
52	Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. European Journal of Neuroscience, 2001, 13, 2077-2087.	1.2	97
53	Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. British Journal of Pharmacology, 1999, 126, 568-571.	2.7	95
54	Effects of Serotonin (5-Hydroxytryptamine, 5-HT) Reuptake Inhibition Plus 5-HT2A Receptor Antagonism on the Firing Activity of Norepinephrine Neurons. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 983-991.	1.3	89

#	Article	IF	CITATIONS
55	Noradrenergic Augmentation of Escitalopram Response by Risperidone: Electrophysiologic Studies in the Rat Brain. Biological Psychiatry, 2007, 61, 671-678.	0.7	85
56	Electrophysiologic Evidence for Desensitization of $\hat{l}\pm 2$ -Adrenoceptors on Serotonin Terminals Following Long-Term Treatment with Drugs Increasing Norepinephrine Synaptic Concentration. Neuropsychopharmacology, 1994, 10, 41-51.	2.8	82
57	Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. Journal of Psychiatry and Neuroscience, 2009, 34, 223-9.	1.4	80
58	The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm. International Journal of Neuropsychopharmacology, 2016, 20, pyw100.	1.0	77
59	Electrophysiological Effects of Repeated Administration of Agomelatine on the Dopamine, Norepinephrine, and Serotonin Systems in the Rat Brain. Neuropsychopharmacology, 2013, 38, 275-284.	2.8	76
60	Short-term lithium treatment enhances responsiveness of postsynaptic 5-HT1A receptors without altering 5-HT autoreceptor sensitivity: An electrophysiological study in the rat brain. Synapse, 1987, 1, 225-232.	0.6	74
61	Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biological Psychiatry, 2001, 50, 191-199.	0.7	73
62	Effects of Acute and Chronic Administration of the Serotonin1A Agonist Buspirone on Serotonin Synthesis in the Rat Brain. Journal of Neurochemistry, 2008, 72, 2022-2031.	2.1	73
63	Prospect of a Dopamine Contribution in the Next Generation of Antidepressant Drugs: The Triple Reuptake Inhibitors. Current Drug Targets, 2009, 10, 1069-1084.	1.0	73
64	Serotonin1A receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABAA receptors: A microiontophoretic study in the rat locus coeruleus. Synapse, 2001, 42, 203-212.	0.6	72
65	Electrophysiological Evidence for the Tonic Activation of 5-HT1A Autoreceptors in the Rat Dorsal Raphe Nucleus. Neuropsychopharmacology, 2004, 29, 1800-1806.	2.8	70
66	Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. European Neuropsychopharmacology, 2000, 10, 177-188.	0.3	68
67	Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. International Journal of Neuropsychopharmacology, 2018, 21, 128-144.	1.0	68
68	Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology, 2020, 45, 606-612.	2.8	68
69	Venlafaxine in Treatment-Resistant Major Depression: A Canadian Multicenter, Open-Label Trial. Journal of Clinical Psychopharmacology, 1999, 19, 401-406.	0.7	68
70	5-HT1D Receptors Regulate 5-HT Release in the Rat Raphe Nuclei In Vivo Voltammetry and In Vitro Superfusion Studies. Neuropsychopharmacology, 1995, 13, 249-260.	2.8	67
71	Effect of acute, short- and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons. Neuropharmacology, 1998, 37, 905-918.	2.0	67
72	Effect of chronic tricyclic antidepressant treatment on the serotoninergic autoreceptor. Naunyn-Schmiedeberg's Archives of Pharmacology, 1980, 314, 123-128.	1.4	66

#	Article	IF	Citations
73	Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive–compulsive disorder. Biological Psychiatry, 1999, 45, 164-174.	0.7	65
74	Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs. Peptides, 2005, 26, 1383-1393.	1.2	65
75	Venlafaxine: Discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. , 1999, 32, 198-211.		63
76	Differential Effect of Gepirone on Presynaptic and Postsynaptic Serotonin Receptors. Journal of Clinical Psychopharmacology, 1990, 10, 13S-20S.	0.7	62
77	Modification of serotonin neuron properties in mice lacking 5-HT1A receptors. European Journal of Pharmacology, 2002, 435, 195-203.	1.7	62
78	Catecholaminergic Strategies for the Treatment of Major Depression. Current Drug Targets, 2006, 7, 149-158.	1.0	62
79	Effects of long-term treatment with the $\hat{l}\pm 2$ -adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 355, 20-29.	1.4	61
80	Functional characterization of a 5â€HT ₃ receptor which modulates the release of 5â€HT in the guineaâ€pig brain. British Journal of Pharmacology, 1993, 108, 13-22.	2.7	60
81	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. Journal of Affective Disorders, 2018, 227, 542-549.	2.0	59
82	Effects of the Selective Norepinephrine Reuptake Inhibitor Reboxetine on Norepinephrine and Serotonin Transmission in the Rat Hippocampus. Neuropsychopharmacology, 2001, 25, 845-857.	2.8	57
83	Neurokinin-1 receptors are decreased in major depressive disorder. NeuroReport, 2002, 13, 1223-1227.	0.6	57
84	On the Safety and Benefits of Repeated Intravenous Injections of Ketamine For Depression. Biological Psychiatry, 2012, 72, e11-e12.	0.7	57
85	Blockade of 5-Hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine. British Journal of Pharmacology, 1998, 125, 526-532.	2.7	56
86	Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology, 2007, 194, 63-72.	1.5	56
87	The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatric Disease and Treatment, 2016, 12, 541.	1.0	56
88	Effect of acute and repeated versus sustained administration of the 5-HT1A receptor agonist ipsapirone: electrophysiological studies in the rat hippocampus and dorsal raphe. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356, 303-311.	1.4	55
89	The Effect of Tryptophan Depletion on Mood in Medication-Free, Former Patients with Major Affective Disorder. Neuropsychopharmacology, 1997, 16, 294-297.	2.8	54
90	Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. In vivo electrophysiological studies in the rat. Neuropharmacology, 2000, 39, 1800-1812.	2.0	54

#	Article	IF	CITATIONS
91	Serotonin 1A Receptor Activation and Hypothermia in Humans Lack of Evidence for a Presynaptic Mediation. Neuropsychopharmacology, 2002, 27, 301-308.	2.8	54
92	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Conce L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. Canadian Journal of Psychiatry, 2021, 66, 113-125.	r10a9nt	54
93	Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain. Neuropharmacology, 2008, 55, 1191-1198.	2.0	52
94	Effect of neurokinin-1 receptor antagonists on the function of 5-HT and noradrenaline neurons. NeuroReport, 2000, 11, 1323-1327.	0.6	51
95	Activation of 5-HT3 receptors enhances the electrically evoked release of [3H]noradrenaline in rat brain limbic structures. European Journal of Pharmacology, 1994, 256, 269-279.	1.7	49
96	Response prediction to antidepressants using scalp and source-localized loudness dependence of auditory evoked potential (LDAEP) slopes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 44, 100-107.	2.5	48
97	Electrophysiological assessment of putative antagonists of 5-hydroxytryptamine receptors: a single-cell study in the rat dorsal raphe nucleus. Canadian Journal of Physiology and Pharmacology, 1989, 67, 98-105.	0.7	47
98	Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission1These results have been reported in part in two publications (Haddjeri et al. 1996,) Tj ETQq0 0	@.n gBT/O)v e7 lock 10
99	Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function. European Neuropsychopharmacology, 2007, 17, 328-338.	0.3	47
100	Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, $\hat{l}\pm 2$ -adrenergic and D2 receptors in the rat brain. European Neuropsychopharmacology, 2009, 19, 177-187.	0.3	47
101	Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. Journal of Affective Disorders, 2011, 128, S3-S10.	2.0	46
102	Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology, 2009, 206, 335-344.	1.5	44
103	The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future Research. International Journal of Neuropsychopharmacology, 2017, 20, pvw072.	1.0	44
104	Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. Journal of Psychiatry and Neuroscience, 2004, 29, 208-18.	1.4	44
105	Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. International Journal of Neuropsychopharmacology, 2007, 10, 41.	1.0	43
106	Altered Function of the Serotonin 1A Autoreceptor and the Antidepressant Response. Neuron, 2010, 65, 1-2.	3.8	43
107	Autoregulatory properties of dorsal raphe 5-HT neurons: Possible role of electrotonic coupling and 5-HT1D receptors in the rat brain. , 1996, 22, 54-62.		42
108	Neurochemical and Psychotropic Effects of Bupropion in Healthy Male Subjects. Journal of Clinical Psychopharmacology, 2003, 23, 233-239.	0.7	42

#	Article	IF	CITATIONS
109	Pharmacotherapies in the Management of Obsessiveâ€"Compulsive Disorder. Canadian Journal of Psychiatry, 2006, 51, 417-430.	0.9	42
110	Selecting Methodologies for the Evaluation of Differences in Time to Response Between Antidepressants. Journal of Clinical Psychiatry, 2002, 63, 694-699.	1.1	41
111	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 207-245.	1.8	40
112	Effects of serotine receptors agonists, TFMPP and CGS12066B, on regional serotonin synthesis in the rat brain: an autoradiographic study. Journal of Neurochemistry, 2002, 80, 788-798.	2.1	38
113	Optimization of vagus nerve stimulation parameters using the firing activity of serotonin neurons in the rat dorsal raphe. European Neuropsychopharmacology, 2009, 19, 250-255.	0.3	38
114	Effects of Sustained Administration of Quetiapine Alone and in Combination with a Serotonin Reuptake Inhibitor on Norepinephrine and Serotonin Transmission. Neuropsychopharmacology, 2012, 37, 1717-1728.	2.8	38
115	Acute Effects of Brexpiprazole on Serotonin, Dopamine, and Norepinephrine Systems: An In Vivo Electrophysiologic Characterization. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 585-595.	1.3	38
116	The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. International Journal of Neuropsychopharmacology, 2020, 23, 230-256.	1.0	38
117	The noradrenergic symptom cluster: clinical expression and neuropharmacology. Neuropsychiatric Disease and Treatment, 2011, 7, 15.	1.0	37
118	Pre-treatment EEG signal variability is associated with treatment success in depression. NeuroImage: Clinical, 2018, 17, 368-377.	1.4	36
119	Effect of repeated electroconvulsive shocks on serotonergic neurons. European Journal of Pharmacology, 1992, 211, 365-373.	1.7	35
120	Neuroscience-based Nomenclature (NbN) for <i>Journal of Psychopharmacology</i> Journal of Psychopharmacology, 2016, 30, 413-415.	2.0	35
121	Pre- and post-synaptic effects of the 5-HT3 agonist 2-Methyl-5-HT on the 5-HT system in the rat brain. Synapse, 1995, 20, 54-67.	0.6	34
122	Effects of sustained gamma-hydroxybutyrate treatments on spontaneous and evoked firing activity of locus coeruleus norepinephrine neurons. Biological Psychiatry, 2004, 55, 934-939.	0.7	34
123	Combination antidepressant therapy for major depressive disorder: Speed and probability of remission. Journal of Psychiatric Research, 2014, 52, 7-14.	1.5	33
124	Antidepressant drug development: Focus on triple monoamine reuptake inhibition. Journal of Psychopharmacology, 2015, 29, 526-544.	2.0	33
125	Effect of sustained administration of the 5-HT1A receptor agonist flesinoxan on rat 5-HT neurotransmission. European Neuropsychopharmacology, 1999, 9, 427-440.	0.3	31
126	Modulation of the firing activity of rat serotonin and noradrenaline neurons by (\hat{A}_{\pm}) pindolol. Biological Psychiatry, 1999, 45, 1163-1169.	0.7	31

#	Article	IF	CITATIONS
127	Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. Journal of Psychiatry and Neuroscience, 2012, 37, 113-121.	1.4	31
128	Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission. European Journal of Pharmacology, 1998, 343, 179-192.	1.7	30
129	Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. Journal of Psychiatry and Neuroscience, 2005, 30, 268-74.	1.4	30
130	Frequency-dependence of serotonin autoreceptor but not ?2-adrenoceptor inhibition of [3H]-serotonin release in rat hypothalamic slices. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 339-339, 60-64.	1.4	29
131	Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of 2 J monoaminergic neurons. Journal of Psychopharmacology, 2010, 24, 1223-1235.	2.0	29
132	Effect of repeated amiflamine administration on serotonergic and noradrenergic neurotransmission: Electrophysiological studies in the rat CNS. Naunyn-Schmiedeberg's Archives of Pharmacology, 1986, 334, 253-260.	1.4	28
133	Electrophysiological impact of trazodone on the dopamine and norepinephrine systems in the rat brain. European Neuropsychopharmacology, 2012, 22, 518-526.	0.3	28
134	The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of Guidelines. International Journal of Neuropsychopharmacology, 2016, 20, pyw091.	1.0	28
135	Functional characterization of 5â€HT _{1D} autoreceptors on the modulation of 5â€HT release in guineaâ€pig mesencephalic raphe, hippocampus and frontal cortex. British Journal of Pharmacology, 1996, 118, 681-689.	2.7	27
136	Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion. Psychopharmacology, 2011, 217, 61-73.	1.5	27
137	Effect of acute and prolonged tianeptine administration on the 5-HT transporter: electrophysiological, biochemical and radioligand binding studies in the rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 351, 111-118.	1.4	26
138	Reduction in serotonin synthesis following acute and chronic treatments with paroxetine, a selective serotonin reuptake inhibitor, in rat brain: an autoradiographic study with α-[14 C]methyl-l-tryptophan 2 2Abbreviations: 5-HT, serotonin, 5-hydroxytryptamine; α-[14C]MTrp, α-[14C]methyl-l-tryptophan; SSRI, selective serotonin content and it-[14C]methyl-l-tryptophan; SSRI, selective serotonin content and it-[14C]methyl-f-HT pinh; SSRI, selective serotonin content and it-[14C]methyl-f-HT pinh; SSRI, selective serotonin content and it-[14C]methyl-f-HT pinh; SSRI, selective serotonin content and it-f-HT pinh;	2.0	26
139	i±-[14C]methyl-5-HT Biochemical Pharmacology, 2001, 62, 1481-1489. Effect of prolonged administration of tianeptine on 5-HT neurotransmission: an electrophysiological study in the rat hippocampus and dorsal raphe. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 351, 119-125.	1.4	25
140	The Effects of Mirtazapine on the Interactions between Central Noradrenergic and Serotonergic Systems. CNS Drugs, 1995, 4, 13-17.	2.7	25
141	Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 357, 600-610.	1.4	25
142	Response of the Norepinephrine System to Antidepressant Drugs. CNS Spectrums, 2001, 6, 679-688.	0.7	25
143	Brain Regional α-[¹¹ C]Methyl- <scp>L</scp> -Tryptophan Trapping in Medication-Free Patients With Obsessive-Compulsive Disorder. Archives of General Psychiatry, 2011, 68, 732.	13.8	25
144	Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacology, 2015, 232, 2343-2352.	1.5	25

#	Article	IF	Citations
145	Diurnal Variation in the Function of Serotonin Terminals in the Rat Hypothalamus. Journal of Neurochemistry, 1989, 52, 453-459.	2.1	24
146	Sustained Administration of Trazodone Enhances Serotonergic Neurotransmission: In Vivo Electrophysiological Study in the Rat Brain. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 197-206.	1.3	24
147	Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. International Journal of Psychiatry in Clinical Practice, 2015, 19, 158-167.	1.2	24
148	5-HT3 receptors which modulate [3H]5-HT release in the guinea pig hypothalamus are not autoreceptors. Synapse, 1993, 15, 143-148.	0.6	23
149	Effect of long-term administration of antidepressant drugs on the 5-HT3 receptors that enhance the electrically evoked release of [3H]noradrenaline in the rat hippocampus. European Journal of Pharmacology, 1994, 271, 121-129.	1.7	23
150	Role of cholinergic and GABAergic systems in the feedback inhibition of dorsal raphe 5-HT neurons. NeuroReport, 2000, 11 , $3397-3401$.	0.6	23
151	Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons. International Journal of Neuropsychopharmacology, 2011, 14, 211-223.	1.0	23
152	Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. International Journal of Neuropsychopharmacology, 2009, 12, 475.	1.0	22
153	Brain Norepinephrine System as a Target for Antidepressant and Mood Stabilizing Medications. Current Drug Targets, 2009, 10, 1061-1068.	1.0	21
154	Altered response to the selective serotonin reuptake inhibitor escitalopram in mice heterozygous for the serotonin transporter: an electrophysiological and neurochemical study. International Journal of Neuropsychopharmacology, 2012, 15, 349-361.	1.0	21
155	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 13-22.	1.8	21
156	Novel attempts to optimize vagus nerve stimulation parameters on serotonin neuronal firing activity in the rat brain. Brain Stimulation, 2012, 5, 422-429.	0.7	20
157	Terminal serotonin autoreceptor function in the rat hippocampus is not modified by pertussis and cholera toxins. Naunyn-Schmiedeberg's Archives of Pharmacology, 1991, 344, 160-166.	1.4	19
158	Early onset of therapeutic action in depression and greater efficacy of antidepressant treatments. International Clinical Psychopharmacology, 1997, 12, S21-S28.	0.9	19
159	Rational site-directed pharmacotherapy for major depressive disorder. International Journal of Neuropsychopharmacology, 2014, 17, 997-1008.	1.0	19
160	Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat. Neuropharmacology, 2000, 39, 1813-1822.	2.0	18
161	Asenapine alters the activity of monoaminergic systems following its subacute and long-term administration: An in vivo electrophysiological characterization. European Neuropsychopharmacology, 2015, 25, 531-543.	0.3	18
162	Electrophysiological examination of the effects of sustained flibanserin administration on serotonin receptors in rat brain. British Journal of Pharmacology, 1999, 126, 627-638.	2.7	17

#	Article	lF	CITATIONS
163	Strategies to achieve clinical effectiveness: Refining existing therapies and pursuing emerging targets. Journal of Affective Disorders, 2011, 132, S21-S28.	2.0	17
164	Effect of Ergotamine on Serotonin-Mediated Responses in the Rodent and Human Brain. Neuropsychopharmacology, 1998, 19, 365-380.	2.8	16
165	In-vivo modulation of central 5-hydroxytryptamine (5-HT1A) receptor-mediated responses by the cholinergic system. International Journal of Neuropsychopharmacology, 2004, 7, 391-399.	1.0	16
166	Examining relations between alpha power as well as anterior cingulate cortex-localized theta activity and response to single or dual antidepressant pharmacotherapies. Journal of Psychopharmacology, 2014, 28, 587-595.	2.0	16
167	A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol. BMC Psychiatry, 2020, 20, 268.	1.1	16
168	Repeated but Not Single Administration of Ketamine Prolongs Increases of the Firing Activity of Norepinephrine and Dopamine Neurons. International Journal of Neuropsychopharmacology, 2021, 24, 570-579.	1.0	16
169	In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre- and postsynaptic 5-HT1A receptors in the rat brain., 1998, 29, 392-405.		15
170	Title is missing!. Journal of Clinical Psychopharmacology, 2003, 23, 233-239.	0.7	15
171	Altered monoamine system activities after prenatal and adult stress: A role for stress resilience?. Brain Research, 2016, 1642, 409-418.	1.1	15
172	Preventing recurrent depression: long-term treatment for major depressive disorder. Journal of Clinical Psychiatry, 2007, 68, e06.	1.1	15
173	Enhancement of serotoninergic function? a sometimes insufficient cause of antidepressant action. Human Psychopharmacology, 2001, 16, 23-27.	0.7	14
174	Assessment of the serotonin reuptake blocking property of YM992: Electrophysiological studies in the rat hippocampus and dorsal raphe., 1999, 34, 277-289.		13
175	Neurokinin-1 receptor antagonists modulate brain noradrenaline and serotonin interactions. European Journal of Pharmacology, 2008, 600, 64-70.	1.7	13
176	Effects of repeated electroconvulsive shocks on catecholamine systems: Electrophysiological studies in the rat brain. Synapse, 2013, 67, 716-727.	0.6	13
177	Modulation of the Antidepressant-Like Effects of Sustained Administration of Carisbamate and Lamotrigine on Monoaminergic Systems: Electrophysiological Studies in the Rat Brain. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 487-496.	1.3	13
178	Restoration of Serotonin Neuronal Firing Following Long-Term Administration of Bupropion but Not Paroxetine in Olfactory Bulbectomized Rats. International Journal of Neuropsychopharmacology, 2015, 18, pyu050-pyu050.	1.0	13
179	Long-term administration of the antidepressant vilazodone modulates rat brain monoaminergic systems. Neuropharmacology, 2015, 99, 696-704.	2.0	13
180	A Neuroscience-Based Nomenclature (NbN) for Psychotropic Agents. International Journal of Neuropsychopharmacology, 2016, 19, pyw066.	1.0	13

#	Article	IF	CITATIONS
181	Physiologic mechanisms underlying the antidepressant discontinuation syndrome. Journal of Clinical Psychiatry, 2006, 67 Suppl 4, 8-13.	1.1	13
182	The importance of serotonin and noradrenaline in anxiety. International Journal of Psychiatry in Clinical Practice, 2007, 11, 16-23.	1.2	12
183	Involvement of 5-HT _{1A} and 5-HT _{2A} Receptors but Not <i>\hat{l}±</i> ₂ -Adrenoceptors in the Acute Electrophysiological Effects of Cariprazine in the Rat Brain In Vivo. Molecular Pharmacology, 2018, 94, 1363-1370.	1.0	12
184	Switching medication products during the treatment of psychiatric illness. International Journal of Psychiatry in Clinical Practice, 2019, 23, 2-13.	1.2	11
185	Flerobuterol, a \hat{l}^2 -adrenoceptor agonist, enhances serotonergic neurotransmission: an electrophysiological study in the rat brain. Psychopharmacology, 1991, 103, 357-365.	1.5	10
186	A framework to avoid irrational polypharmacy in psychiatry. Journal of Psychopharmacology, 2012, 26, 1507-1511.	2.0	10
187	Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 115, 110507.	2.5	10
188	Brexpiprazole Alters Monoaminergic Systems following Repeated Administration: an in Vivo Electrophysiological Study. International Journal of Neuropsychopharmacology, 2016, 19, pyv111.	1.0	9
189	Synergistic effect of aripiprazole and escitalopram in increasing serotonin but not norepinephrine neurotransmission in the rat hippocampus. Neuropharmacology, 2019, 146, 12-18.	2.0	9
190	Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition. Neuropsychopharmacology, 2020, 45, 2098-2105.	2.8	9
191	Ketamine for chronic depression: two cautionary tales. Journal of Psychiatry and Neuroscience, 2019, 44, 384-385.	1.4	9
192	Atypical antipsychotics for mood and anxiety disorders: safe and effective adjuncts?. Journal of Psychiatry and Neuroscience, 2005, 30, 232-3.	1.4	9
193	Enhancing action of LSD on neuronal responsiveness to serotonin in a brain structure involved in obsessive–compulsive disorder. International Journal of Neuropsychopharmacology, 2003, 6, 13-21.	1.0	8
194	Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biological Psychiatry, 2001, 50, 644.	0.7	7
195	The separate and combined effects of monoamine oxidase A inhibition and nicotine on the mismatch negativity event related potential. Pharmacology Biochemistry and Behavior, 2015, 137, 44-52.	1.3	7
196	Partial inhibition of catecholamine activity and enhanced responsiveness to NMDA after sustained administration of vortioxetine. Neuropharmacology, 2018, 128, 425-432.	2.0	7
197	Optimal use of antidepressants: when to act?. Journal of Psychiatry and Neuroscience, 2009, 34, 80.	1.4	7
198	The Effects of Ketamine on Cognition in Unipolar and Bipolar Depression. Journal of Clinical Psychiatry, 2022, 83, .	1.1	7

#	Article	IF	CITATIONS
199	The benzodiazepine receptor inverse agonist DMCM decreases serotonergic transmission in rat hippocampus: An in viovo electrophysiological study. Synapse, 1990, 6, 175-178.	0.6	6
200	Effect of long-term administration of the antidepressant drug milnacipran on serotonergic and noradrenergic neurotransmission in the rat hippocampus. Life Sciences, 2007, 81, 166-176.	2.0	6
201	Progress on the Neuroscience-Based Nomenclature (NbN) for Psychotropic Medications. Neuropsychopharmacology, 2017, 42, 1927-1928.	2.8	6
202	Electrophysiological Investigation of the Effects of Antidepressant Treatments on Serotonin Receptors., 1990,, 499-504.		6
203	Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials. Journal of Affective Disorders, 2017, 210, 273-279.	2.0	5
204	Long-term administration of cariprazine increases locus coeruleus noradrenergic neurons activity and serotonin _{1A} receptor neurotransmission in the hippocampus. Journal of Psychopharmacology, 2020, 34, 1143-1154.	2.0	5
205	Triple reuptake inhibition of serotonin, norepinephrine, and dopamine increases the tonic activation of l±2-adrenoceptors in the rat hippocampus and dopamine levels in the nucleus accumbens. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 103, 109987.	2.5	5
206	Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2022, 25, 283-292.	1.0	5
207	Effect of the \hat{I}^2 -adrenoceptor agonist flerobuterol on serotonin synthesis in the rat brain. Biochemical Pharmacology, 2000, 59, 673-679.	2.0	4
208	The separate and combined effects of monoamine oxidase A inhibition and nicotine on resting state EEG. Journal of Psychopharmacology, 2016, 30, 56-62.	2.0	4
209	Optimized regimens of combined medications for the treatment of major depressive disorder: a double-blind, randomized-controlled trial. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 3209-3218.	1.0	4
210	Toward Optimal Treatments for Major Depression. CNS Spectrums, 2002, 7, 148-154.	0.7	3
211	An enhancement of the firing activity of dopamine neurons as a common denominator of antidepressant treatments?. International Journal of Neuropsychopharmacology, 2012, 15, 551-553.	1.0	3
212	Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. Focus (American Psychiatric Publishing), 2020, 18, 236-243.	0.4	3
213	Augmentation strategies in treatment resistant depression: Preclinical and clinical aspects. European Psychiatry, 1998, 13, 207S-207S.	0.1	1
214	Blier and de Montigny reply. Trends in Pharmacological Sciences, 1995, 16, 17.	4.0	0
215	Reply to Smith Letter. American Journal of Psychiatry, 2010, 167, 995-996.	4.0	0
216	The usefulness of large studies in psychopharmacology: understanding their strong points and their drawbacks. Journal of Psychiatry and Neuroscience, 2007, 32, 232-3.	1.4	0